Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751127 · ClinicalTrials.gov registry record · Phase 3
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
NCT00751127: Completed Phase 3 study, sponsored by Pfizer.
NCT00751127 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 268 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00751127, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
Study Summary
PhXA41 is not inferior to timolol
Interventions
- DRUG PhXA41
- DRUG timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 1993-01 |
| Est. Completion | 1994-02 |
| Phase | Phase 3 |
What the finished NCT00751127 record still lists
NCT00751127 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which PhXA41 is the first listed.
NCT00751127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00751127 about?
NCT00751127 is a clinical study titled "A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension". PhXA41 is not inferior to timolol
What is the current status of trial NCT00751127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 1993-01. Estimated completion is 1994-02.
What interventions are being tested in trial NCT00751127?
The interventions under investigation include: PhXA41 (DRUG), timolol (DRUG).
Who is sponsoring clinical trial NCT00751127?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00751127's enrollment target sits among peer trials
268 1222nd of 2000 higher than 779 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia